Semaglutide was originally created to treat patients with diabetes, however, a secondary application was later found as a medicine used for weight loss, to lower blood sugar levels, and to reduce the risk of major cardiovascular events such as heart attack or stroke in type two diabetes patients.
‍
Semaglutide is a GLP-1 agonist and works by increasing insulin release, lowering the amount of glucagon released, delaying gastric emptying, and reducing appetite.

Semaglutide is not for use in people with type 1 diabetes.

Each of the different brands of semaglutide (Wegovy, Ozempic, Rybelus) is FDA approved for different conditions.